CAP—advancing the evaluation of preclinical Alzheimer disease treatments

If we are to find treatments to postpone, reduce the risk of, or completely prevent the clinical onset of Alzheimer disease (AD), we need faster methods to evaluate promising preclinical AD treatments, new ways to work together in support of common goals, and a determination to expedite the initiati...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Nat Rev Neurol
Asıl Yazarlar: Reiman, Eric M., Langbaum, Jessica B., Tariot, Pierre N., Lopera, Francisco, Bateman, Randall J., Morris, John C., Sperling, Reisa A., Aisen, Paul S., Roses, Allen D., Welsh-Bohmer, Kathleen A., Carrillo, Maria C., Weninger, Stacie
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4847536/
https://ncbi.nlm.nih.gov/pubmed/26416539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrneurol.2015.177
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller